Search

everythinglearnresearchcommunity

for

Search:↓

A 27-year-old male is using a hair loss treatment regimen including topical minoxidil, oral finasteride, dermarolling, ketoconazole shampoo, and mesotherapy with dutasteride and vitamins. He is considering switching to oral dutasteride as recommended by his doctor and questions the necessity and cost of mesotherapy.

The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.

The conversation is about users trying to regain access to a Discord server related to pp405 research, with differing opinions on the effectiveness of pp405 for hair loss. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned in the conversation.

The user has mostly recovered hair density using finasteride, alternating oral and topical minoxidil, and occasional dermarolling, but the crown area is still struggling. Advice includes continuing treatment for up to 24 months and possibly consulting a doctor if issues persist.

Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.

The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.

User noticed hair growth after 1.5 months using Fin, Min, stemoxydine, dermarolling, nizoral, and scalp massage. Others commented on promising results and potential improvement in 6 months.

The user is experiencing hair regrowth after using spironolactone, minoxidil 5%, and various supplements. They plan to purchase men's minoxidil for cost efficiency and use Nizoral shampoo and an oil blend for hair care.

The user reports significant hair regrowth after 10 months using 1 mg oral finasteride daily and a 1.25 mm derma stamp bi-weekly with rosemary and jojoba oil. Other users commend the progress and inquire about the routine and side effects.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

The conversation is about the effectiveness of Stemoxydine for hair loss. People are discussing its benefits and comparing it to other treatments like Minoxidil, Finasteride, and RU58841.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

A user shared their 12-month hair loss treatment progress using Minoxidil, Finasteride, Nioxin shampoo, scalp massages, and tea tree oil. They report a 40% improvement and satisfaction with the results.

27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

This conversation is about a user's progress pictures after 10 months of using the hair loss treatments finasteride and minoxidil. Other users responded with compliments and questions about the dosage used.

A user trying various treatments for hair loss, such as minoxidil, stemoyxidine, alfatradiol, and microneedling, with plans to add tretinoine and finasteride.

The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

A user received KX-826 instead of RU58841 and is confused about their order. They are asking if others have experienced similar issues.

Koshine is considered less effective than finasteride, dutasteride, and RU58841 for hair loss treatment. One user reported positive results with Koshine, but others found it ineffective.

The user shared six months of progress using oral finasteride (1.2mg) and minoxidil (3mg) with positive results. They do not use topical minoxidil and have not experienced side effects like erectile dysfunction.

User shared progress pictures after 9 months of using minoxidil, finasteride, spironolactone, and estradiol for hair loss. Significant regrowth was noted, especially after starting estradiol.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Plant-based exosomes for hair loss lack scientific evidence and are considered high-risk with low evidence. Combining PRF with minoxidil and finasteride is suggested as a better option.

User Crazy-Signature930 shares progress on oral minoxidil for eyelashes and eyebrows. Others comment on the impressive results and ask about side effects and duration of use.

The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.